LinkGevity
AI-driven longevity biotech developing first-in-class anti-necrotic drugs, starting with kidney disease.
- Biotech & Life Sciences
- Cambridge
- Sector
- Biotech & Life Sciences
- Stage
- Undisclosed
- Based in
- Cambridge
- Founded
- 2023
- Funding raised
- Undisclosed
- Website
- linkgevity.com
LinkGevity is a longevity biotech based at the Babraham Research Campus near Cambridge. Building on its Blueprint Theory of ageing, it uses an AI platform that reclassifies biomedical data to map the biological triggers of age-related decline. Its lead programme is a class of necrosis inhibitors it calls Anti-Necrotics, with a candidate for acute kidney injury being prepared for Phase 2, plus non-clinical uses in tissue engineering and organ preservation offered for licensing. Founded in 2023 by sisters Dr Carina Kern and Serena Kern-Libera, it has received support from the Francis Crick Institute's KQ Labs, Innovate UK and the UK Space Agency.
Team
More startups in the directory
Boone
Nutrition app that analyses meals from photos, barcodes and receipts, with optional DNA insights.
Vocavio
AI voice analytics that measure team communication performance in high-pressure training.
KIT-AR
Augmented reality and AI software that guides manufacturing workers to cut assembly errors and quality costs.
Entropyst
Electrified reactor technology that converts methane and ammonia into clean hydrogen and carbon materials.
InfraFund
Platform for tokenised investment in renewable energy projects, letting communities co-own local clean energy.
UGiftMe
Online platform for buying and sending digital gift cards and vouchers from 1,000+ brands, with a wallet to swap them.
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.